Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31743082 | 0.82 | GRM2 (0.49) | GRM2CYP19A1METAP2 | |
| SCHEMBL12059121 | 0.82 | BRD4 (0.51) | GRM2 | |
| SCHEMBL29809484 | 0.82 | BRD4 (0.51) | GRM2 | |
| SCHEMBL16651514 | 0.82 | GRM2 (0.49) | GRM2 | |
| SCHEMBL23187978 | 0.80 | CYP11B2 (0.64) | GRM2CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL31743111 | 0.78 | PDE10A (0.46) | GRM2 | |
| SCHEMBL31006551 | 0.78 | GRM2 (0.73) | GRM2CYP11B2CYP11B1CYP19A1ERN1 | |
| SCHEMBL29283802 | 0.78 | GRM2 (0.73) | GRM2CYP11B2CYP11B1CYP19A1ERN1 | |
| SCHEMBL31006541 | 0.77 | GRM2 (0.69) | GRM2CYP11B2CYP11B1CYP19A1ERN1 | |
| SCHEMBL29283804 | 0.77 | GRM2 (0.69) | GRM2CYP11B2CYP11B1CYP19A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | WASHINGTON UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | BECN1, TFEB, ATG7 | GRM2 850/4885CYP11B2 1536/4885CYP11B1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.